Member since 22 December 201701 February 2018 at 14:29
The so-called racial gap in breast cancer care has long been suggested by researchers, with black and Hispanic women less likely to get recommended breast cancer treatments than white patients. Researchers claim financial factors such as economic and social class or access to insurance alone can't explain this "gap”. Even after accounting for those differences, racial disparities in breast cancer care can still be found. For hormone receptor testing there may not be such differences but the gap persists in other interventions. For instance, black women have lower odds of receiving recommended treatments: interventions like mastectomy or breast-conserving therapy or even chemotherapy. The sad part is, these disparities persist even after many studies accounted for insurance coverage and socioeconomic status. People often are quick to blame the so-called "racial gap" on income or insurance, but the fact that the gap exists independently of these factors clearly hints there are more "hidden" racial biases in our healthcare system.
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epitheli....
Various techniques have been tried by patients and recommended by physicians to prevent, lessen the severity or treat chemotherapy side effects such as peripheral neuropathy. There is no "one-size-fits-all" regimen that works for everyone. Much of the treatment is based on trial and error and find....
Nidii Berwal
The so-called racial gap in breast cancer care has long been suggested by researchers, with black and Hispanic women less likely to get recommended breast cancer treatments than white patients. Researchers claim financial factors such as economic and social class or access to insurance alone can't explain this "gap”. Even after accounting for those differences, racial disparities in breast cancer care can still be found. For hormone receptor testing there may not be such differences but the gap persists in other interventions. For instance, black women have lower odds of receiving recommended treatments: interventions like mastectomy or breast-conserving therapy or even chemotherapy. The sad part is, these disparities persist even after many studies accounted for insurance coverage and socioeconomic status. People often are quick to blame the so-called "racial gap" on income or insurance, but the fact that the gap exists independently of these factors clearly hints there are more "hidden" racial biases in our healthcare system.